Emyria Limited (ASX:EMD)

Market Cap	41.01M
Revenue (ttm)	1.39M
Net Income (ttm)	-3.14M
Shares Out	804.17M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,051,723
Average Volume	1,693,096
Open	0.0530
Previous Close	0.0530
Day's Range	0.0510 - 0.0550
52-Week Range	0.0210 - 0.0780
Beta	0.20
RSI	37.85
Earnings Date	Dec 2, 2025

About Emyria

Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia. The company operates through Clinical Services, Clinical Services, and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression. The company also develops ultra-pure CBD capsules (EMD-RX7, and EMD-RX9) and proprietary MDMA analogues, as well as provides psychological trauma care facility under the Pax Centre name. It has a collaboration partnersh...

• Industry: Health Information Services
• Sector: Healthcare
• Founded: 2018
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: EMD

Financial Performance

In 2025, Emyria's revenue was 1.39 million, a decrease of -36.68% compared to the previous year's 2.20 million. Losses were -3.14 million, -72.57% less than in 2024.